System and method for efficiently distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device and an external system

• US 7,756,572 B1
• Filed: 04/25/2007
• Issued: 07/13/2010
• Est. Priority Date: 01/25/2005
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Bornzin, Gene, Boileau, Peter, Gill, Jong, Fard, Mohssen, Min, Xiaoyi, Reiss, Josh, Jalali, Laleh, Zhu, Bing, Snell, Jay
• Primary Examiner(s): Kahelin; Michael
• Application Number:
  US11/740,175
• Time in Patent Office: 1,175 Days
• Field of Search: 600/516, 600/517
• US Class Current: 600/517
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/358 Detecting ST segments
• CPC Class Codes: A61B 5/36 Detecting PQ interval, PR interval or QT interval
• CPC Class Codes: A61B 5/364 Detecting abnormal ECG interval, e.g. extrasystoles, ectopic heartbeats
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood
• CPC Class Codes: A61N 1/36585 controlled by two or more physical parameters

Abstract

Techniques are described for efficiently detecting and distinguishing among cardiac ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. In one example, a preliminary indication of an episode of cardiac ischemia is detected based on shifts in ST segment elevation within the IEGM. In response, the implanted device then records additional IEGM data for transmission to an external system. The external system analyzes the additional IEGM data to confirm the detection of cardiac ischemia using a more sophisticated analysis procedure exploiting additional detection parameters. In particular, the external system uses detection parameters capable of distinguishing hypoglycemia, hyperglycemia and hyperkalemia from cardiac ischemia, such as QTmax and QTend intervals. Alternatively, the more sophisticated analysis procedure may be performed by the device itself, if it is so equipped. Other examples described herein pertain instead to the detection of atrial fibrillation.

Claims

1. A method for use with an implantable medical device for detecting cardiac ischemia within a patient in which the device is implanted, the method comprising:

detecting ST segment elevation within electrical cardiac signal data;

detecting a preliminary indication of an episode of cardiac ischemia based on ST segment elevation and, in response, sensing additional electrical cardiac signal data;

detecting QTmax intervals and QTend intervals within the additional data;

analyzing the QTmax intervals and the QTend intervals to detect for changes in QTmax intervals and changes in QTend intervals, wherein said changes in QTmax intervals and QTend intervals include lengthening or decreases in said intervals; and

confirming the episode of cardiac ischemia based on the combination of a decrease in the QTmax intervals and a lack of significant change in the QTend intervals, or distinguishing among cardiac ischemia and other potential causes of ST segment deviation based on other changes in the QTmax intervals and the QTend intervals.

2. The method of claim 1 wherein analyzing the QTmax intervals and QTend intervals to confirm the detection of cardiac ischemia is performed using a system external to the patient following transmission of the additional electrical cardiac signal data from the implanted device to the external system.

3. The method of claim 2 further including forwarding a notification of the medical condition from the external system to a medical professional.

4. The method of claim 2 wherein the external system includes a centralized processor and a transtelephonic relay device and wherein the transtelephonic relay device relays the additional electrical cardiac signal data from the implanted device of the patient to the centralized processor.

5. The method of claim 1 wherein analyzing the QTmax intervals and QTend intervals and confirming the episode of cardiac ischemia is performed by the implantable device itself.

6. The method of claim 1 wherein the ST segments are representative of intervals between the ends of depolarization events (QRS-complexes) and the beginnings of corresponding repolarization events (T-waves).

7. The method of claim 1 wherein detecting a preliminary indication of an episode of cardiac ischemia based on ST segment elevation includes detecting a shift in ST segment elevation based on a predetermined number of heartbeats.

8. The method of claim 1 wherein analyzing the QTmax intervals and QTend intervals and confirming the episode of cardiac ischemia include analyzing QTmax intervals and QTend intervals recorded during a predetermined period of time.

9. The method of claim 8 wherein the predetermined period of time for confirming the episode of cardiac ischemia is at least four hours.

10. The method of claim 1 wherein:

QTmax intervals are representative of intervals between the start of depolarization events and the peaks of corresponding repolarization events; and

QTend intervals are representative of intervals between the start of depolarization events and the ends of corresponding repolarization events.

11. The method of claim 1 wherein distinguishing among cardiac ischemia and other potential causes of ST segment deviation includes:

distinguishing an episode of hypoglycemia or other systemic QT prolongation condition from cardiac ischemia based on a significant lengthening of one or more of QTmax intervals and QTend intervals.

12. The method of claim 1 wherein distinguishing among cardiac ischemia and other potential causes of ST segment deviation includes

distinguishing an episode of hyperglycemia from cardiac ischemia based on a significant change in ST segment elevation in combination with a lack of significant change in both the QTend intervals and the QTmax intervals.

13. The method of claim 1 wherein distinguishing among cardiac ischemia and other potential causes of ST segment deviation includes

distinguishing an episode of hyperkalemia from cardiac ischemia based on a significant change in ST segment elevation in combination with a significant decrease in both the QTend intervals and the QTmax intervals.

14. The method of claim 1 further including the step of generating a warning signal in response to detection of a preliminary indication of cardiac ischemia.

15. A system for detecting cardiac ischemia within a patient, the system comprising:

an implantable medical device comprising;

a data acquisition system configured to acquire electrical cardiac signal data;

memory configured to record electrical cardiac signal data;

an ST segment elevation detector operative to detect ST segment elevation within electrical cardiac signal data; and

a cardiac ischemia detector operative to detect a preliminary indication of an episode of cardiac ischemia based on ST segment elevation and, in response, further operative to control the recording of additional cardiac signal data; and

a cardiac ischemia confirmation system operative to detect QTmax intervals and QTend intervals within the additional data;

analyze the QTmax intervals and the QTend intervals to detect for changes in QTmax intervals and changes in QTend intervals, wherein said changes in QTmax intervals and QTend intervals include lengthening or decreases in said intervals; and

confirm the episode of cardiac ischemia based on the combination of a decrease in the QTmax intervals and a lack of significant change in the QTend intervals, or distinguish among cardiac ischemia and other potential causes of ST segment deviation based on other changes in the QTmax intervals and the QTend intervals.

16. The system of claim 15 wherein the cardiac ischemia confirmation system is a component of the implanted device.

17. The system of claim 15 wherein the cardiac ischemia confirmation system is a component of a device external to the patient.

18. A system for use with an implantable medical device for detecting and distinguishing certain medical conditions within a patient in which the device is implanted, the system comprising:

means for detecting ST segment elevation within electrical cardiac signal data;

means for detecting a preliminary indication of an episode of cardiac ischemia based on ST segment elevation and, in response, for controlling the recording of additional electrical cardiac signal data;

means for detecting QTmax intervals and QTend intervals within the additional data;

means for analyzing the QTmax intervals and the QTend intervals to detect for changes in QTmax intervals and changes in QTend intervals, wherein said changes in QTmax intervals and QTend intervals include lengthening or decreases in said intervals; and

means for confirming the episode of cardiac ischemia based on the combination of a decrease in the QTmax intervals and a lack of significant change in the QTend intervals, or distinguishing among cardiac ischemia and hypoglycemia, hyperglycemia and hyperkalemia based on other changes in the QTmax intervals and the QTend intervals.